Clindamycin phosphate suppository

Bacterial vaginosis is associated with microbial infections such as Bacteroides, Gardnerella vaginalis, Mycoplasma hominis, and Streptococcus. In vitro tests have shown that clindamycin can effectively antagonize these microorganisms. Although this product is inactive in vitro, anaerobic bacteria and Gardnerella in the vagina can produce a large amount of phosphatase, which hydrolyzes clindamycin phosphate into clindamycin, and produces an effect. Clindamycin acts on the 50S subunit of the bacterial ribosome, inhibiting the elongation of the peptide chain and inhibiting the synthesis of bacterial proteins, thereby eliminating the A protein and the villi-like coat on the surface of the bacteria, making it easy to be phagocytosed and killed. Animal experiments have shown that this product has no carcinogenic and mutagenic effects and does not affect the mating and fertility of animals.

Clindamycin. Chemical name: (2S-trans)-6-(1-methyl-4-propyl-2-pyrrolidinecarbonyl)-1-thio-methyl-7-chloro-6,7,8-trideoxy-L-threo-a-D-galactopyranoside-2-dihydrogen phosphate Molecular weight: C18H34ClN2O8PS

This product is a white or off-white suppository made of a fatty matrix.

Used to treat bacterial vaginosis.

Vaginal administration: once a day, after washing the vulva before going to bed at night, put 0.1g (1 tablet) of this product into the posterior fornix of the vagina for 7 consecutive days. Or follow the doctor's advice.

Domestic clinical studies have shown that adverse reactions to clindamycin phosphate suppositories include candidal vaginitis, candidal infection, vulvar redness and swelling, skin itching, and urticaria. Laboratory tests also showed changes in hemoglobin, white blood cells, neutrophils, platelets, and liver and kidney function, but none of them had clinical significance. Foreign clinical studies on clindamycin phosphate suppositories reported that 589 patients used clindamycin phosphate suppositories, with an adverse reaction rate of 10.5%, of which 3 cases (0.5%) discontinued treatment. Adverse reactions include: Urogenital system: functional disorders (3.4%), vaginal pain (1.9%), and candidal vaginitis (1.5%). Systemic effects: fungal infection (1.0%). Adverse reactions with an incidence of 1%: Urogenital system: menstrual disorders, dysuria

1. Patients with a history of allergy to clindamycin, lincomycin or other components of this product are contraindicated. 2. Patients with a history of localized enteritis, ulcerative enteritis or antibiotic-related enteritis are contraindicated.

Precautions for children: data is still lacking. Precautions for pregnancy and lactation: 1. Pregnant women should weigh the pros and cons before deciding whether to use this product. It is generally not suitable for use. 2. If lactating women use this product, they should stop breastfeeding. Precautions for the elderly: There are not enough clinical cases to prove whether there is a difference in the use of clindamycin phosphate vaginal preparations between people over 65 years old and young people.

1. Clindamycin phosphate can enhance the effects of neuromuscular blockers, so the two should not be used together. 2. Clindamycin phosphate and erythromycin have antagonistic effects, so they should not be used together.

Keep tightly closed in a cool place.

0.1g (calculated as clindamycin)

24 months

Kunshan Peili Pharmaceutical Co., Ltd.

• Founded in:

  1995-03-02

• Address:

  No. 27, Lufeng West Road, Lujia Town, Kunshan City, Jiangsu Province

• Tax NO.:

  91320583608279361D

• Registered Funds:

  $3.3 million

• Website:

  Log in to view

• Email:

  Log in to view